280 completed. 280 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 280 | Completed 280 |
Follow Depressive Disorder: new trials by email Literature Review of Depressive Disorder trials Research Report on Depressive Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression Esketamine 56 mg, Esketamine 84 mg - Depressive Disorder, Treatment-Resistant | Phase 4 | Completed | Janssen Korea, Ltd., Korea | 47 | 2025-06-09 | 2026-08-03 |
| Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia Valbenazine - Schizophrenia, Schizoaffective Disorder | Phase 4 | Completed | Neurocrine Biosciences | 59 | 2023-05-09 | 2026-01-16 |
| Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression VTS-K - Treatment Resistant Depression, Major Depressive Disorder | Phase 4 | Completed | Theresa Jacob, PhD, MPH | 15 | 2022-12-06 | 2026-04-21 |
| SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Sertraline, Bupropion - Major Depressive Disorder | Phase 4 | Completed | Mclean Hospital | 133 | 2022-09-30 | 2025-09-08 |
| The BIomarker Guided (BIG) Study for Depression Guanfacine Tablets - Major Depressive Disorder | Phase 4 | Completed | Stanford University | 28 | 2022-09-14 | 2025-03-20 |
| Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression Midazolam (active placebo), Ketamine and Midazolam (active placebo), Ketamine - Treatment-resistant Depression, Major Depressive Disorder | Phase 4 | Completed | Taipei Veterans General Hospital, Taiwan | 12 | 2022-03-15 | 2025-09-05 |
| Repurposing of Dextromethorphan as an Adjunct Therapy in Patients With Major Depressive Disorder Selective Serotonin Reuptake Inhibitors, Dextromethorphan, Placebo - Major Depressive Disorder | Phase 4 | Completed | All India Institute of Medical Sciences, Bhubaneswar | 60 | 2022-02-10 | 2023-12-22 |
| Sustained Mood Improvement With Laughing Gas Exposure: A Randomized Controlled Pilot Trial Nitrous Oxide 99 %, Oxygen + Midazolam - Treatment Resistant Depression, Major Depressive Disorder | Phase 4 | Completed | Unity Health Toronto | 40 | 2021-11-03 | 2024-05-08 |
| A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting ZULRESSO® - Postpartum Depression | Phase 4 | Completed | Supernus Pharmaceuticals, Inc. | 52 | 2021-10-08 | 2025-09-15 |
| Stellate Ganglion Block for Major Depressive Disorder. Bupivacaine Hydrochloride, Normal Saline - Treatment Resistant Depression, Major Depressive Disorder | Phase 4 | Completed | Unity Health Toronto | 10 | 2021-09-23 | 2024-02-09 |
| Integrating a Stepped Care Model of Screening and Treatment for Depression Into Malawi's National HIV Care Delivery Platform Problem Management Plus, Antidepressant Therapy - Depressive Disorder | Phase 4 | Completed | RAND | 487 | 2021-09-01 | 2026-06-09 |
| Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder Sarcosine and SSRI, Placebo and SSRI - Major Depressive Disorder | Phase 4 | Completed | All India Institute of Medical Sciences, Bhubaneswar | 60 | 2021-08-26 | 2023-07-25 |
| Clonidine to Prevent Delirium After Electroconvulsive Therapy. Clonidine, Placebo - Major Depressive Disorder, Catatonia | Phase 4 | Completed | Insel Gruppe AG, University Hospital Bern | 130 | 2021-04-27 | 2026-05-19 |
| A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment Esketamine, SSRI/SNRI - Depressive Disorder, Major | Phase 4 | Completed | Janssen-Cilag Ltd. | 183 | 2021-04-26 | 2025-09-18 |
| Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder Brexpiprazole - Major Depressive Disorder | Phase 4 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 122 | 2021-04-01 | 2024-02-02 |
| A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression Esketamine 56 mg, Esketamine 84 mg, Placebo - Depressive Disorder, Treatment-Resistant | Phase 4 | Completed | Janssen Research & Development, LLC | 477 | 2020-11-04 | 2025-04-25 |
| Ketamine for Older Adults Pilot Ketamine - Treatment Resistant Depression, Refractory Depression | Phase 4 | Completed | Washington University School of Medicine | 25 | 2020-10-22 | 2023-02-14 |
| Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses Buprenorphine, Naltrexone, Oral Placebo - Major Depressive Disorder, Depression | Phase 4 | Completed | Marta Peciña, MD PhD | 120 | 2020-10-19 | 2026-07-31 |
| Ketamine Treatment Effects on Synaptic Plasticity in Depression Ketamine - Major Depressive Disorder | Phase 4 | Completed | New York State Psychiatric Institute | 9 | 2020-10-09 | 2023-11-13 |
| A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine Agomelatine, Placebos - Major Depressive Disorder | Phase 4 | Completed | Central South University | 137 | 2020-10-01 | 2024-04-01 |
Showing 20 of 280. Sign in to see all of them.
Depressive Disorder, Major (222) · Depression (118) · Depressive Disorder, Treatment-Resistant (18) · Dysthymic Disorder (16) · Bipolar Disorder (15) · Anxiety Disorders (14) · Mood Disorders (10) · Depression, Postpartum (7) · Cognitive Dysfunction (5) · Mental Disorders (5) · Premenstrual Dysphoric Disorder (5) · Suicidal Ideation (5) · Premenstrual Syndrome (4) · Psychological Well-Being (4)
Mental Disorders (275) · Mood Disorders (270) · Behavior (123) · Behavioral Symptoms (119) · Pathological Conditions, Signs and Symptoms (28) · Nervous System Diseases (26) · Signs and Symptoms (18) · Neurologic Manifestations (17) · Bipolar and Related Disorders (15) · Central Nervous System Diseases (11) · Pathologic Processes (11) · Brain Diseases (9) · Neurocognitive Disorders (9) · Urogenital Diseases (8)
Escitalopram (54) · Duloxetine Hydrochloride (30) · Bupropion (19) · Ketamine (18) · Sertraline (18) · Venlafaxine Hydrochloride (15) · Fluoxetine (11) · Paroxetine (11) · Citalopram (10) · Vortioxetine (9) · Mirtazapine (8) · Aripiprazole (7) · Dexetimide (7) · Selective Serotonin Reuptake Inhibitors (7) · Interpersonal Psychotherapy (6)
New York State Psychiatric Institute (26) · Eli Lilly and Company (14) · University of California, Los Angeles (14) · Massachusetts General Hospital (9) · University of Pittsburgh (9) · Emory University (7) · Forest Laboratories (6) · H. Lundbeck A/S (5) · Mclean Hospital (5) · National Institute of Mental Health (NIMH) (5) · University of Texas Southwestern Medical Center (5) · Capital Medical University (4) · Pfizer (4) · Stanford University (4) · University of Pennsylvania (4)
United States (175) · Canada (24) · South Korea (14) · China (10) · France (9) · Italy (9) · Germany (8) · Spain (7) · Russia (6) · Taiwan (6) · Sweden (5) · Australia (4) · Denmark (4) · Israel (4) · Netherlands (4)
David J. Hellerstein, MD (4) · Ian A Cook, MD (4) · Amit Anand, MD (3) · Bret Rutherford, MD (3) · Helen Lavretsky, M.D. (3) · Jonathan W. Stewart, M.D. (3) · Warren D Taylor, MD, MHSc (3) · Alexander W McIntyre, FRCPC (2) · Carl Gommoll, MS (2) · Cynthia N Epperson, MD (2)
PMID 25758058, PMID 25980552, PMID 26709542, PMID 26803397, PMID 29608461, PMID 34183490, PMID 35592490, PMID 36999619, PMID 39428602, PMID 42214294, PMID 11806859, PMID 12813115, PMID 14627997, PMID 15729083, PMID 15939837, PMID 16086624, PMID 16390886, PMID 16426099, PMID 16457894, PMID 16540613, PMID 16551710, PMID 16554525, PMID 16554526, PMID 16566612, PMID 16566901, PMID 16636629, PMID 16642436, PMID 16690084, PMID 16754414, PMID 16816220, PMID 16824617, PMID 16946176, PMID 16946177, PMID 16946178, PMID 16974189, PMID 17015814, PMID 17074942, PMID 17091129, PMID 17195602, PMID 17302619, PMID 17389902, PMID 17431740, PMID 17559755, PMID 17685736, PMID 17727882, PMID 17854250, PMID 17934551, PMID 18039992, PMID 18162024, PMID 18162025
1RC1MH088438 (1), 2004 (1), 2005 (1), 2008 (1), 2016 (1), 2018 (1), 2019 (1), K12HD001441 (1), K23MH064196 (1), K23MH067060 (1), K23MH067894 (1), K23MH076049 (1), K23MH085236 (1), K23MH099097 (1), K23MH105569 (1)